CapForce (OPGN) Q1 2024 earnings summary

Executive summary

• Revenue for Q1 2024 was $168,149, down 82% year-over-year, mainly due to the deconsolidation of Curetis and Ares Genetics after their insolvency filings in late 2023.

• The company shifted focus to strategic alternatives, including a potential sale or reverse merger, following new leadership and board changes in March 2024.

• Operations have been scaled down to core Nasdaq listing functions, with minimal distribution, marketing, and sales support.

Financial highlights

• Net income for Q1 2024 was $386,033, compared to a net loss of $5,736,603 in Q1 2023, driven by a $2.1 million gain on lease indemnification.

• Total operating expenses decreased 69% year-over-year to $1.87 million, reflecting the absence of Curetis and Ares Genetics and cost-cutting measures.

• Cash and cash equivalents were $267,493 as of March 31, 2024, with restricted cash of $302,262.

• Product sales fell 66% to $141,373, while laboratory services increased 24% to $26,776; collaboration revenue was $0.

Outlook and guidance

• Management expects current cash to fund operations only into Q3 2024 and expresses substantial doubt about the company's ability to continue as a going concern without additional funding or a strategic transaction.

• The company is actively seeking a sale, reverse merger, or other strategic alternatives.